Patient-specific treatment planning for clinical interstitial ultrasound thermal ablation of focal prostate cancer

Catheter-based interstitial ultrasound applicators, previously applied for delivering hyperthermia in the prostate, and the TheraVision system are FDA 510(k) cleared for soft tissue ablation. In the present study, 3D patient-specific finite difference models representing prostate and focal disease were developed and applied to (1) develop pre-treatment planning tools and (2) evaluate the temperature/thermal dose distributions as a means to optimize the ultrasound applicator parameters and positioning for controlled and selective ultrasound thermal ablation of focal prostate cancer.